Patent application number | Description | Published |
20130280638 | FUSED POWDER OF YTTRIA-STABILISED ZIRCONIA - The present invention relates to a powder of molten grains of yttria-stabilised zirconia, said grains having the following chemical analysis, in weight percent on the basis of the oxides:
| 10-24-2013 |
20130323597 | METHOD FOR THE PRODUCTION OF AN LMO PRODUCT - A fused product including lithium-manganese spinel, which is optionally doped, having a spinel structure AB | 12-05-2013 |
20140158933 | METHOD FOR PRODUCING A FUSED PRODUCT - A method for manufacturing a molten material (the crystallized portion of which consists of a single crystalline phase), includes a) mixing raw materials so as to form a feedstock; b) melting the feedstock until a liquid mass reaches a temperature higher than the melting temperature Tf of the molten material obtained at the end of step e); c) cooling until the liquid mass is completely solidified to obtain a molten material, the amorphous phase of which is constitutes less than 80 wt % thereof; d) optionally crushing/grinding and/or performing selection by particle size on the molten material; e) optionally, heat-treating the molten material at a temperature which is an increment lower than the melting temperature of the molten material and is between Tf−800° C. (or 500° C.) and Tf−50° C., for a period of time in a reducing environment; and f) optionally, crushing/grinding and/or performing selection by particle size on said molten material. | 06-12-2014 |
Patent application number | Description | Published |
20090048212 | COSMETIC COMPOSITION COMPRISING AN OIL - Cosmetic composition comprising an oil The present invention relates to a composition for making up or caring for the skin in the form of a water-in-oil emulsion comprising an aqueous phase, at least 5% by weight, relative to the total weight of the composition, of a dispersed solid phase and a liquid fatty phase having at least one non-volatile fraction, the said liquid fatty phase comprising at least one first oil chosen from slow volatile oils with an evaporation rate of between 0.002 and 0.05 mg/cm | 02-19-2009 |
20090130152 | COSMETIC COMPOSITION COMPRISING AN OIL - The present invention relates to a composition for making up or caring for the skin having a volatile fraction, a non-volatile fraction and comprising at least one dispersed solid phase and a liquid fatty phase comprising: —at least one oil chosen from dry oils chosen from oils with a viscosity of less than or equal to 10 Cps, a surface tension of between 21 and 31 mN/m and an evaporation rate of less than 0.002 mg/cm2/minute, the said dispersed solid phase being present in the composition in a content such that the volume fraction of the dispersed solid phase is greater than or equal to 55% by volume and in particular ranges from 55% to 98% by volume relative to the total volume of the non-volatile fraction of the composition. The invention also relates to the use of the said composition for obtaining a uniform makeup that does not transfer, that shows good staying power and/or is comfortable. | 05-21-2009 |
20090275532 | COSMETIC COMPOSITION COMPRISING AN OIL - The present invention relates to a cosmetic composition for making up or caring for the skin in the form of a water-in-oil emulsion comprising an aqueous phase and at least 15% by weight, relative to the total weight of the composition, of a fatty phase comprising at least one liquid fatty phase having at least one non-volatile fraction, the said liquid fatty phase comprising at least one dry oil chosen from oils with a viscosity of less than or equal to 10 Cps, a surface tension of between 21 and 31 mN/m and an evaporation rate of less than 0.002 mg/cm2/minute, the said dry oil being present in the emulsion in a content ranging from 55% to 100% by weight relative to the total weight of the non-volatile fraction of the liquid fatty phase, the said liquid fatty phase being such that the calculated weight ratio of the liquid fatty phase remaining in the composition after 10 minutes of drying, to the initial liquid fatty phase, ranges from 0.75 to 1. The invention also relates to the use of the said composition for obtaining a uniform makeup and/or a makeup that does not transfer. | 11-05-2009 |
20110129431 | COMPOSITION CONTAINING A POLYORGANOSILOXANE POLYMER, A THICKENING AGENT AND AT LEAST ONE VOLATILE ALCOHOL - The invention relates to a physiologically acceptable composition, especially a cosmetic composition, comprising (a) at least one polyorganosiloxane containing polymer comprising at least one moiety which comprises at least one polyorganosiloxane group consisting of 1 to about 1000 organosiloxane units in the chain of the moiety or in the form of graft, and at least two groups capable of establishing hydrogen interactions; (b) at least one volatile alcohol; and (c) at least one thickening agent, as well as to methods of using such compositions and kits containing such compositions. | 06-02-2011 |
20110142897 | PROCESS FOR TREATMENT OF KERATINOUS MATERIALS AND KIT FOR FORMULATION OF A COSMETIC PRODUCT - Kit for formulation of a cosmetic product in emulsion form containing a composition A containing oil and a gelling agent which is in dispersed form, composition A containing less than 10% by weight of water, and an aqueous composition B, compositions A and B being packed separately. Compositions A and B are intended to be mixed on the spot to form a product in emulsion form which can be a make-up product, or for removing make-up or cleaning the skin or for care of the skin, mucous membranes, integuments or hair. Process of using product. | 06-16-2011 |
20130280197 | AQUEOUS COSMETIC COMPOSITION COMPRISING ALKYLCELLULOSE - A cosmetic composition includes, in a physiologically acceptable medium: at least water, at least alkylcellulose, at least one first hydrocarbon-based non-volatile oil, chosen from: C10-C26 alcohols, preferably monoalcohols; optionally hydroxylated monoesters, diesters or triesters of a C2-C8 monocarboxylic or polycarboxylic acid and of a C2-C8 alcohol; esters of a C2-C8 polyol and of one or more C2-C8 carboxylic acids. At least one second non-volatile oil chosen from silicone oils and/or fluoro oils or hydrocarbon-based oils other than the said first oil; at least one stabilizer chosen from surfactants and/or hydrophilic gelling agents, preferably chosen from associative polymers, natural polymers and their mixture. | 10-24-2013 |
20140050679 | COSMETIC COMPOSITION COMPRISING A CUCURBIC ACID COMPOUND AND A BLEND OF SULFONIC AND ACRYLIC POLYMERS - The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a cucurbic acid compound of formula (I) | 02-20-2014 |
20140341953 | BUBBLE ENCAPSULATION VIA SILICILIC ACID COMPLEXATION - Disclosed are methods of preparing stable gas-in-water dispersions by silicic acid complexation of micron-sized gas bubbles, and stable dispersions prepared by silicic acid complexation. Compositions and products comprising the dispersions are also disclosed. Dispersions may be stable over an extended period of time at room temperature. | 11-20-2014 |
20140341954 | STABLE EMULSIONS VIA PARTICLE ABSORPTION BY ELECTROSTATIC INTERACTION - Disclosed are methods of preparing stable O/W emulsions by particle adsorption via electrostatic interaction, and stable emulsions prepared by particle adsorption via electrostatic interaction. Compositions and products comprising the emulsions are also disclosed. Emulsions may be stable over an extended period of time at room temperature. | 11-20-2014 |
20140341955 | STABLE BUBBLES VIA PARTICLE ABSORPTION BY ELECTROSTATIC INTERACTION - Disclosed are methods of preparing stable gas-in-solution emulsions by particle adsorption via electrostatic interaction, and stable emulsions prepared by particle adsorption via electrostatic interaction. Compositions and products comprising the emulsions are also disclosed. Emulsions may be stable over an extended period of time at room temperature. | 11-20-2014 |
20140341981 | EMULSION STABILIZATION VIA SILICILIC ACID COMPLEXATION - Disclosed are methods of preparing stable O/W emulsions by silicic acid complexation of micron-sized oil droplets, and stable emulsions prepared by silicic acid complexation. Compositions and products comprising the emulsions are also disclosed. Emulsions may be stable over an extended period of time at room temperature. | 11-20-2014 |
Patent application number | Description | Published |
20100040555 | Magnetic Nanoparticles Compositions and Uses Thereof - The present invention relates to the use of a biocompatible nanoparticle or nanoparticle aggregate, in combination with an external non-oscillating magnetic field, wherein said nanoparticle comprises: a) a core comprising magnetic material; b) a biocompatible shell surrounding the core, and, optionally; c) a labelling agent wherein the outer diameter of the shell is less than about 100 nm, to prepare a composition, wherein the composition is deprived of any cell targeting means. The present invention further relates to the compositions thus obtained and to their uses in the field of human health, for the treatment of cancer, or in diagnostic (imaging for example), for the monitoring of tumor evolution. | 02-18-2010 |
20110213192 | Inorganic Nanoparticles of High Density to Destroy Cells In-Vivo - The present application relates to novel excitable particles which can be used in the health sector. It more particularly relates to particles which can generate electrons and/or high energy photon when excited by ionizing radiations such as X- Rays, γ-Rays, radioactive isotope and/or electron beams, and to the uses thereof in health, in particular in human health. The inventive particles are made of an inorganic material comprising oxygen, in particular an oxide, said material having an adequate density, and can be activated in vitro, ex vivo, or in vivo, by controllable external excitation, in order to disturb, alter or destroy target cells, tissues or organs. The invention also relates to methods for the production of said particles, and to pharmaceutical or medical device compositions containing same. | 09-01-2011 |
20120203050 | METALLIC NANOPARTICLES, PREPARATION AND USES THEREOF - The present application relates to activable nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cells, tissues or organs. It more particularly relates to nanoparticles which can generate a significantly efficient therapeutic effect, when exposed to ionizing radiations. The inventive nanoparticle is a metallic nanoparticle having, as the largest size, a size comprised between about 80 and 105 nm, the metal having preferably an atomic number (Z) of at least 25. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses. | 08-09-2012 |
20140056813 | NANOPARTICLES DELIVERY SYSTEMS, PREPARATION AND USES THEREOF - The present application relates to thermosensitive liposomes encapsulating nanoparticles which can be used in the health sector, in particular in human health. The invention also relates to pharmaceutical and diagnostic compositions comprising thermosensitive liposomes as defined previously, as well as to their uses. | 02-27-2014 |
20140335015 | NANOPARTICLES COMPRISING METALLIC AND HAFNIUM OXIDE MATERIALS, PREPARATION AND USES THEREOF - The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof. | 11-13-2014 |
Patent application number | Description | Published |
20100291082 | ANTIGEN PRESENTING CELL TARGETED ANTI-VIRAL VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 11-18-2010 |
20100297114 | ANTIGEN PRESENTING CELL TARGETED VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 11-25-2010 |
20100322929 | ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 12-23-2010 |
20110182937 | Dendritic Cell Vaccines - Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-α), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS). | 07-28-2011 |
20120244155 | Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine - Compositions and methods comprising high affinity monoclonal antibody conjugates against several DC receptors are described herein. The inventors prepared fusion proteins with antigens for DC-targeting vaccine generation by conjugating several | 09-27-2012 |
20120301465 | COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS - Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C. | 11-29-2012 |
20140127198 | Antigen Presenting Cell Targeted Anti-Viral Vaccines - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 05-08-2014 |
20140199763 | COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS - Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C. | 07-17-2014 |